OCM
CLVS

Objective Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Objective Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,272
Closed -$29K – 96
2022
Q3 		$29K Hold
24,272
– – 0.03% 88
2022
Q2 		$44K Buy
+24,272
New +$35.8K 0.04% 94

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Objective Capital Management's CLVS Position: Q4 2022 in Review

Objective Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 24,272 shares — an estimated $29K sold.

Objective Capital Management first reported a position in CLVS in Q2 2022 and held it in 2 quarters. The position peaked at $44K in Q2 2022. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Objective Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Objective Capital Management sold 24,272 Clovis Oncology, Inc. shares in Q4 2022, an estimated $29K.
  • Objective Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2022 and held it in 2 quarters.
  • Objective Capital Management's Clovis Oncology, Inc. position peaked at $44K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Objective Capital Management's 13F filing for Q4 2022, filed 27 Feb 2023.